论文信息 - Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation. - 字舞流文

Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.

G. Leone | L. Laurenti | M. Blasi | G. Savino | S. Sica | R. Battendieri | M. Tarnani | L. De Padua

[1] V. Cohen,et al. Treatment options for ocular adnexal lymphoma (OAL) , 2009, Clinical ophthalmology.

[2] I. Lossos,et al. Extranodal marginal zone lymphoma of the ocular adnexa. , 2009, Blood.

[3] R. Dummer,et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. , 2008, Blood.

[4] D. Heo,et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[5] A. Vincent-Salomon,et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. , 2006, Blood.

[6] D. Meller,et al. Anti‐CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva , 2004, European journal of haematology.

[7] A. Ferreri,et al. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. , 2011, Ophthalmology.

[8] G. Martinelli,et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. , 2005, Haematologica.